SCHEMBL5364426

SCHEMBL5364426

Cc1cc(C)c(C=C2C(=O)Nc3ccc(OCC(O)CO)cc32)[nH]1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 10/20 0.67
KDR P35968 6/20 0.60
PDPK1 O15530 2/20 0.60
PDGFRB P09619 4/20 0.59
FLT3 P36888 4/20 0.57
ALK Q9UM73 4/20 0.57
TLK2 Q86UE8 1/20 0.57
PAK4 O96013 1/20 0.56
CSF1R P07333 2/20 0.55
FGFR1 P11362 2/20 0.55
SRC P12931 2/20 0.55
FLT1 P17948 2/20 0.55
FGFR3 P22607 2/20 0.55
MAPK1 P28482 2/20 0.55
FLT4 P35916 2/20 0.55
PDGFRA P16234 2/20 0.55
NTRK1 P04629 2/20 0.55
ABL1 P00519 2/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370007 0.81 RET (0.42) RETKDRPDPK1TLK2PAK4
SCHEMBL19816 0.81 RET (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL19817 0.81 RET (1.00) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5368750 0.81 RET (0.71) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5358502 0.80 LRRK2 (0.42) RETPDPK1TLK2PAK4NTRK1
SCHEMBL7493570 0.80 NTRK1 (0.64) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5369734 0.80 PDGFRB (0.64) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5357699 0.78 RET (0.73) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5361502 0.78 PDPK1 (0.64) RETKDRPDPK1PDGFRBFLT3
SCHEMBL5364424 0.77 KDR (0.72) RETKDRPDPK1PDGFRBFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK RET 283/4885KDR 239/4885PDPK1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.